At the time of writing, Cidara Therapeutics Inc [CDTX] stock is trading at $109.24, up 0.19%. An important factor to consider is whether the stock is rising or falling in short-term value. The CDTX shares have gain 17.31% over the last week, with a monthly amount glided 10.90%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Cidara Therapeutics Inc [NASDAQ: CDTX] stock has seen the most recent analyst activity on October 16, 2025, when Morgan Stanley initiated its Overweight rating and assigned the stock a price target of $190. Previously, JP Morgan started tracking the stock with Overweight rating on October 10, 2025, and set its price target to $200. Citizens JMP started tracking the stock assigning a Mkt Outperform rating and suggested a price target of $46 on March 12, 2025. RBC Capital Mkts started tracking with a Outperform rating for this stock on December 13, 2024, and assigned it a price target of $34. In a note dated November 08, 2024, Guggenheim initiated a Buy rating and provided a target price of $33 on this stock.
For the past year, the stock price of Cidara Therapeutics Inc fluctuated between $12.66 and $121.21. Currently, Wall Street analysts expect the stock to reach $156.75 within the next 12 months. Cidara Therapeutics Inc [NASDAQ: CDTX] shares were valued at $109.24 at the most recent close of the market. An investor can expect a potential return of 43.49% based on the average CDTX price forecast.
Analyzing the CDTX fundamentals
According to Cidara Therapeutics Inc [NASDAQ:CDTX], the company’s sales were 0.00M for trailing twelve months, which represents an -100.00% plunge. To continue investigating profitability, this company’s Return on Assets is posted at -0.17, Equity is -0.4 and Total Capital is -0.26. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.0.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 106.29 points at the first support level, and at 103.35 for the second support level. However, for the 1st resistance point, the stock is sitting at 112.59, and for the 2nd resistance point, it is at 115.95.
Ratios To Look Out For
It is important to note that Cidara Therapeutics Inc [NASDAQ:CDTX] has a current ratio of 16.45. On the other hand, the Quick Ratio is 16.45, and the Cash Ratio is 15.8.
Transactions by insiders
Recent insider trading involved Davarpanah Nicole Negar, Chief Medical Officer, that happened on Sep 11 ’25 when 474.0 shares were sold. Director, RA CAPITAL MANAGEMENT, L.P. completed a deal on Jun 26 ’25 to buy 2.27 million shares. Meanwhile, Director Mineo Chrysa bought 2270.0 shares on Jun 02 ’25.
